The incidence rates of BIM deletion polymorphism in EGFR‐mutant patients with advanced‐stage NSCLC were 11.3% (22/194) and 17.0% (24/141) in the CTONG0901 and GLCI cohorts, respectively. Here, EGFR is linked to non-small cell lung carcinoma.